Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma

Lung-Yi Mak; Kwan-Lung Ko; Wai-Pan To; Danny Ka-Ho Wong; Wai-Kay Seto; James Fung; Man-Fung Yuen

추천

검색

자료유형: 학술저널

저자정보: Lung-Yi Mak (The University of Hong Kong) Kwan-Lung Ko (The University of Hong Kong) Wai-Pan To (The University of Hong Kong) Danny Ka-Ho Wong (The University of Hong Kong) Wai-Kay Seto (The University of Hong Kong) James Fung (The University of Hong Kong) Man-Fung Yuen (The University of Hong Kong)

저널정보: 거트앤리버 발행위원회 Gut and Liver Gut and Liver 제14권 제5호

발행연도: 2020.1

수록면: 665 - 668 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Serum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. We investigated the longitudinal profile of HBcrAg in entecavir (ETV)-treated CHB patients with subsequent HCC development. We identified HCC cases diagnosed at ≥1 year after ETV initiation. CHB patients without HCC (matched for age, sex, cirrhosis status, baseline hepatitis B virus [HBV] DNA level, and ETV treatment duration) were identified as controls at an HCC:non-HCC ratio of 1:2. Serum samples were retrieved at baseline (ETV initiation) and at 3 and 5 years of ETV therapy for HBcrAg measurement (log IU/mL). In total, 180 patients (60 HCC patients matched with 120 CHB patients without HCC; median age, 56.5 years; 80.6% male; baseline HBV DNA, 5.9 log IU/mL; median follow-up, 6.8 years) were recruited. The median time from ETV initiation to HCC development was 3.2 years. HBcrAg levels were higher in HCC cases than in controls at all three time points: 5.69 log IU/ mL versus 5.02 log IU/mL (p=0.025), 4.23 log IU/mL versus 3.36 log IU/mL (p=0.007), and 3.86 log IU/mL versus 3.36 log IU/mL (p=0.009), respectively. ETV led to similar rates of decline in HBcrAg from baseline to 3 years in both groups (0.34 log IU/mL/year vs 0.39 log IU/mL/year, p=0.774), although the decline from 3 to 5 years was slower in the non- HCC group (0.05 log IU/mL/year) than in the HCC group (0.09 log IU/mL/year, p=0.055). ETV time-dependently reduced HBcrAg in HCC and non-HCC patients. HBcrAg interpretation should consider the antiviral treatment duration.

#Entecavir #Hepatocellular carcinoma #Hepatitis B core-related antigen #Chronic hepatitis B

참고문헌 (15)

참고문헌 신청

Varbobitis I / 2016 / The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy / Clin Mol Hepatol 22:319~326

Papatheodoridis GV / 2011 / Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s)starting with lamivudine monotherapy : results of the nationwide HEPNET : Greece cohort study / Gut 60:1109~1116

Papatheodoridis GV / 2015 / Risk of hepatocellular carcinoma in chronic hepatitis B : assessment and modification with current antiviral therapy / J Hepatol 62:956~967

Hosaka T / 2013 / Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection / Hepatology 58:98~107

European Association for the Study of the Liver / 2017 / EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection / J Hepatol 67:370~398

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!